Telephone
61.3.9824.5254
Address
Level 3, Suite 1 62 Lygon Street Carlton South, Victoria (VIC) 3053
Description
Arovella Therapeutics Ltd. engages in the development invariant Natural Killer (iNKT) cell platform for treatment of cancer. Its technologies include iNKT cell therapy, CAR19-iNKT + CF33-CD19, CLDN18.2-iNKT, and DKK1-CAR-iNKT. The company was founded on December 21, 1999 and is headquartered in Carlton South, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.02 - 0.11
Trade Value (12mth)
AU$40,158.00
1 week
7.23%
1 month
-1.11%
YTD
270.83%
1 year
270.83%
All time high
14.7798
EPS 3 yr Growth
-76.500%
EBITDA Margin
%
Operating Cashflow
-$6m
Free Cash Flow Return
-75.20%
ROIC
-103.40%
Interest Coverage
-36.20
Quick Ratio
4.40
Shares on Issue (Fully Dilluted)
671m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 22 |
Quarterly Appendix 4C and Activities Report
×
Quarterly Appendix 4C and Activities Report |
31 January 23 |
Quarterly Appendix 4C and Activities Report
×
Quarterly Appendix 4C and Activities Report |
31 January 22 |
Quarterly Appendix 4C and Activities Report
×
Quarterly Appendix 4C and Activities Report |
31 January 22 |
Becoming a substantial holder
×
Becoming a substantial holder |
31 August 23 |
Response to ASX Price Query
×
Response to ASX Price Query |
31 August 23 |
Appendix 4E and Annual Report
×
Appendix 4E and Annual Report |
31 August 23 |
Corporate Governance Statement
×
Corporate Governance Statement |
31 August 23 |
Appendix 4G
×
Appendix 4G |
31 August 23 |
2023 ESG Report
×
2023 ESG Report |
31 August 22 |
Preliminary Final Report
×
Preliminary Final Report |
30 October 23 |
AusBiotech Invest Presentation
×
AusBiotech Invest Presentation |
30 November 22 |
Proposed issue of securities - ALA
×
Proposed issue of securities - ALA |
30 January 23 |
Change in substantial holding
×
Change in substantial holding |
29 September 22 |
Annual Report to shareholders
×
Annual Report to shareholders |
29 September 22 |
Corporate Governance Statement
×
Corporate Governance Statement |
29 September 22 |
Appendix 4G
×
Appendix 4G |
29 November 22 |
R&D Tax Incentive refund received
×
R&D Tax Incentive refund received |
29 November 21 |
R&D Tax Incentive refund received
×
R&D Tax Incentive refund received |
29 June 23 |
Share Purchase Plan (SPP) Closing Date Extended
×
Share Purchase Plan (SPP) Closing Date Extended |
29 June 23 |
Update - Proposed issue of securities - ALA
×
Update - Proposed issue of securities - ALA |
29 June 22 |
Notification regarding unquoted securities - ALA
×
Notification regarding unquoted securities - ALA |
29 July 22 |
Quarterly Appendix 4C and Activities Report
×
Quarterly Appendix 4C and Activities Report |
28 November 23 |
Application for quotation of securities - ALA
×
Application for quotation of securities - ALA |
28 November 23 |
Notice Under Section 708A
×
Notice Under Section 708A |
28 March 23 |
Arovella iNKT Cell Platform Explanatory Webinar
×
Arovella iNKT Cell Platform Explanatory Webinar |
28 June 22 |
Sumatriptan Update
×
Sumatriptan Update |
28 February 22 |
Appendix 4D and Half Year Report
×
Appendix 4D and Half Year Report |
28 February 22 |
Update - Proposed issue of securities - ALA
×
Update - Proposed issue of securities - ALA |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.